Vertex director granted 2,866 stock options
Vertex Pharmaceuticals director Bruce I. Sachs reported an acquisition of stock options as compensation.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Vertex Pharmaceuticals director Bruce I. Sachs reported an acquisition of stock options as compensation. He received a grant of 2,866 stock options for Vertex common stock at an exercise price of $424.45 per share. The options are fully vested and expire on April 30, 2036, and his direct derivative holdings after this grant total 2,866 options.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 2,866 | $0.00 | $0.00 |
Footnotes (1)
- F1. Fully vested.
Key Figures
Key Terms
Stock Option (Right to Buy) financial
exercise price financial
expiration date financial
Common Stock financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did VRTX director Bruce I. Sachs report?
What is the exercise price of Bruce I. Sachs’s VRTX stock options?
How many VRTX stock options does Bruce I. Sachs hold after this Form 4?
Are Bruce I. Sachs’s newly granted VRTX options already vested?
When do Bruce I. Sachs’s VRTX stock options expire?
AI-generated analysis. How Rhea-AI works. Not financial advice.